Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Magnesium in clinical stroke

Jeffrey L. Saver  1 , Sidney Starkman  1
Robert Vink  1 , Mihai Nechifor  2
, editors.
In: Magnesium in the Central Nervous System [Internet]. Adelaide (AU): University of Adelaide Press; 2011.
Affiliations
Free Books & Documents
Review

Magnesium in clinical stroke

Jeffrey L. Saver et al.
Free Books & Documents

Excerpt

Stroke is the second leading cause of death and a leading cause of disability worldwide. Unfortunately, current therapies for acute ischemic stroke are of extremely limited effectiveness. The ideal neuro- protective agent for stroke would be inexpensive, readily available, easy to administer and have no significant adverse side effects. Intravenous magnesium sulphate offers promise as just such an agent. In clinical trials to date, administration of magnesium sulphate has shown favourable trends toward neuroprotection in resuscitated cardiac arrest patients, in cardiac bypass surgery and carotid endarterectomy. In acute stroke, eight pilot clinical trials of magnesium sulphate have shown good safety, and the subset of pilot trials with randomized controls have shown favourable effects on clinical outcome point estimates. The first phase 3 trial of magnesium sulphate for focal stroke was the Intravenous Magnesium Efficacy in Stroke (IMAGES) Trial. Hampered by late administration of the study agent, IMAGES overall produced a neutral result, but exploratory analyses identified early (under 3 hour), lacunar stroke, haemorrhagic stroke, and severely hypertensive patients as having a potential differential beneficial response to magnesium that deserved further investigation. The Field Administration of Stroke Therapy – Magnesium (FAST-MAG) trial has been specifically designed to test magnesium in the hyperacute time window by initiating therapy in the prehospital setting.

PubMed Disclaimer

References

    1. Adams HP, Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655–711. - PubMed
    1. Alberts MJ. Hyperacute stroke therapy with tissue plasminogen activator. Am J Cardiol. 1997;80(4C):29D–34D. - PubMed
    1. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, Gottwald MD, O'Neil N, Neuhaus JM, Segal MR, Lowenstein DH. A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus. N Engl J Med. 2001;345:631–7. - PubMed
    1. Aslanyan S, Weir CJ, Muir KW, Lees KR. Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke. 2007;38:1269–73. - PubMed
    1. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557–63. - PubMed

LinkOut - more resources